CommercialCoverageMedium impact
07.11.02f, Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Independence Blue Cross·Pulmonology, Allergy & Immunology, Internal Medicine +1 more·Medical Policy
Effective date
Jun 24, 2026
We identified it
Jun 25, 2026
Summary
Policy 07.11.02f regarding measurement of exhaled nitric oxide and breath condensate for asthma and respiratory disorder diagnosis and management has been reissued effective 06/24/2026. The billing team must review the full policy text to identify any changes to coverage criteria, billing codes, prior authorization requirements, or documentation standards compared to the previous version.
Action Required
By 06/24/2026: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=06&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#commercial-07-11-02f to identify specific billing codes, prior authorization requirements, and documentation changes. Update billing system rules, encounter templates, and provider guidance accordingly. Document all changes in internal compliance procedures. Without the full policy content, specific billing codes and workflow changes cannot be identified from this summary notice alone.